Botulinum Toxin Market Size, Share & Trends Analysis Report By Product Type (Type A, Type B), By Application (Therapeutic, Aesthetic), By End Use, By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global botulinum toxin market size was valued at USD 5.8 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 11.5% from 2022 to 2030. Botulinum toxin is a protein and neurotoxin produced by the bacterium clostridium botulinum. The toxin is a selective blocker of acetylcholine released from nerves that block neural transmission from the nerves when injected into the muscle. Botulinum toxin is one of the most exceptional substances encountered in medicine and science. The adoption of botulinum toxin in cosmetology has grown rapidly over the decade, and at present, it is one of the most common and widely performed aesthetic procedures in the world. The increasing concerns over aesthetic features in developed and developing regions have led to an increase in the number of cosmetic procedures. 

The availability of a variety of botulinum toxin products such as Botox, Xeomin, and disport will accelerate the market growth. The increasing usage of botulinum toxin injection in several aesthetic procedures including the treatment of glabellar lines, chemical browlift, and forehead lines is expected to boost the market growth over the coming years. Presently, a few products of botulinum toxin–Type-A and only one product of Type-B (Myobloc) are commercially available in the market. However, rising investment in R&D activities by major manufacturers to explore the therapeutic use of botulinum toxin is building opportunities for the expansion of its therapeutic application area in the near future. 

The coronavirus outbreak impacted all industries including cosmetics as there were strict restrictions imposed by the authority bodies as a precautionary measure. The supply chain for aesthetic products was also affected. The pandemic caused a huge disruption in the demand-supply of the overall medical device industry. However, there was a rise in the botulinum toxin sale due to the rising demand for botox during the pandemic. In the past 20 years, the number of aesthetic botox treatments has surged more than 700%, with over 6 million procedures or treatments performed every year. The demand for cosmetic treatments, including botox and fillers, had increased rapidly since the COVID-19 pandemic began.  

Product Type Insights

The botulinum toxin-A segment held the largest revenue share of over 95.0% in 2021 and is anticipated to grow at a significant rate over the forecast period due to a rise in customer preference owing to advantages including minimal pain, no blood loss, and lack of scarring during the procedure. Botulinum toxin type-A has been increasingly utilized to treat chronic migraine, tension-type headache, and other primary neurological disorders. Based on product type, the market is classified into botulinum toxin type-A and botulinum toxin type-B.

Botulinum toxin type-A products are adopted for a range of therapeutic and aesthetic applications, and with the rising demand for aesthetic beauty, the segment is likely to grow further in the near future. Also, various botulinum toxin type-A products including Botox and Dysport are commercially available in the market and have been clinically tested and proven to be safe and effective in the long term with the least side effects.

Application Insights

The therapeutic segment dominated the market in 2021 with a revenue share of over 50.0%. Botulinum toxin is known to be the most potent known biological neurotoxin molecule and it holds great promise in the treatment of many disorders. The therapeutic benefits of botulinum toxin have been diversifying due to a deeper understanding of its different mechanisms of action and molecular behavior. Botox procedures are adopted for various therapeutic and preventive treatments for disorders such as chronic migraine, conditions such as hyperhidrosis, and over-reactive bladders. By application, the market is segmented into aesthetic and therapeutic applications.

The aesthetic segment is expected to expand at a significant CAGR of 12.2% during the forecast period. Botulinum toxin (BoNT), a bacterially produced neurotoxin, is a mainstay in the cosmetology armamentarium. The rising consciousness regarding aesthetic appearance and rising technological advancements in developed and developing countries have led to an increase in the number of cosmetic surgeries.

End-use Insights

The hospitals' segment accounted for the largest revenue share of over 50.0% in 2021. The rising number of hospitals with advanced care and facilities in developed and developing countries and increasing awareness regarding aesthetic procedures performed are contributing to the segment growth. Furthermore, a maximum number of therapeutic procedures such as dystonia, spasticity, and chronic migraine are being performed in the hospitals. Based on end-use, the market is segmented into hospitals, dermatology clinics, and spas and cosmetic clinics. 

The spas and cosmetic centers segment are likely to expand at a CAGR of 12.5% from 2022 to 2030. A higher preference for aesthetic procedures in dermatology clinics and spas and cosmetic centers is significantly contributing to the segment growth. Plastic surgeons and medical spa owners are seeing an increase in customers. In addition, the rising number of medical spas and cosmetic centers in regions like the Asia Pacific are contributing to the market growth. 

Regional Insights

North America accounted for the largest revenue share of 35.0% in 2021 owing to the increasing disposable income and a growing number of cosmetic procedures. For instance, in 2019, as per the American Society of Plastic Surgeons (ASPS), 1.3 million surgeries were performed with botulinum toxin products. Thus, increasing the use of botulinum toxin products in various cosmetic procedures performed in the region will stimulate market growth in North America.

The Asia Pacific region is expected to register the highest CAGR of 14.2% over the forecast period owing to favorable reimbursement, a large patient population, and the availability of developed healthcare facilities in many countries.

In countries such as South Korea, China, and Japan, there is higher beauty consciousness and aesthetic awareness, hence likely to drive the market. Furthermore, the rising number of medical spas and cosmetic centers in countries like Thailand, Singapore, and Malaysia is expected to drive the market in the region. 

Key Companies & Market Share Insights

The global market is competitive and highly regulated. The major players in the industry are taking up key business strategies such as product innovations, new product launches, strategic partnerships & collaborations, joint ventures, advanced service launches, and contracts to strengthen their position and acquire a major share in the market. 

For instance, in July 2020, Tenjin Pharma and Merz Pharma collaboratively signed up for a sale of Xeomin (incobotulinumtoxinA) of Tenjin Pharma for intramuscular injection in 50, 100, and 200 units for the treatment of lower limb spasticity, which is also approved by Japan’s Ministry of Health. This strategy of the company will help the organization to add value to its business products portfolio, thereby strengthening its revenue generation stream. Some prominent players in the global botulinum toxin market include:

Botulinum Toxin Market Report Scope

Global Botulinum Toxin Market Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global botulinum toxin market report based on product type, application, end-use, and region:

• Product Type Outlook (Revenue, USD Billion, 2018 - 2030)

  • Type A

    • Botox

    • Dysport

    • Xeomin

    • Others

  • Type B

• Application Outlook (Revenue, USD Billion, 2018 - 2030)

  • Therapeutic

    • Chronic Migraine

    • Overactive Bladder

    • Cervical Dystonia

    • Spasticity

    • Others

  • Aesthetic

    • Glabellar Lines

    • Crow’s Feet

    • Forehead Lines

    • Others

• End-use Outlook (Revenue, USD Billion, 2018 - 2030)

  • Hospitals

  • Dermatology Clinics

  • Spas & Cosmetic Centers

• Regional Outlook (Revenue, USD Billion, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • India

    • Japan

    • China

    • South Korea

    • Australia

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE